Evidence mapPaperPMID 32238407Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2020

Wei Deng, Hongliang Liu, Sheng Luo, Jeffrey Clarke, Carolyn Glass, Li Su, Lijuan Lin, David C Christiani, Qingyi Wei

Open access · greenAbstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Wei DengDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.ORCID 0000-0003-0946-5579
Hongliang LiuDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina.
Sheng LuoDepartment of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
Jeffrey ClarkeDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Carolyn GlassDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.ORCID 0000-0002-8850-9906
Li SuDepartments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, Massachusetts.ORCID 0000-0002-6453-199X
Lijuan LinDepartments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
David C ChristianiDepartments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, Massachusetts.ORCID 0000-0002-0301-0242
Qingyi WeiDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina. qingyi.wei@duke.edu.ORCID 0000-0002-3845-9445
Duke University · USGuangxi Medical University · CNMassachusetts Department of Public Health · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Shannon Jones McCall · 1985 to 2026
$174.8M
Statistical Methods for Analysis of Massive Genetic and Genomic Data in Cancer ResearchR35CA197449 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI XIHONG LIN · 2015 to 2026
$10.9M
Molecular and Genetic Analysis of Lung Cancer SurvivalR01CA092824 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 2002 to 2013
$5.9M
GENETIC SUSCEPTIBILITY TO LUNG CANCERR01CA074386 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI CHRISTIANI, DAVID C · 1997 to 2008
$4.8M
Statistical Methods for Clinical Trials with Multivariate Longitudinal OutcomesR01NS091307 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI LUO, SHENG · 2015 to 2018
$1.2M
NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA074386NCI NIH HHS R01 CA092824NCI NIH HHS R35 CA197449NINDS NIH HHS R01 NS091307
6 · The paper itself

Abstract

backgroundSeveral oncogenic signals are involved in the synthesis, metabolism, transportation, and modulation of cholesterol. However, the roles of genetic variants of the cholesterol pathway genes in cancer survival remain unclear.

methodsWe investigated associations between 26,781 common SNPs in 209 genes of the cholesterol pathway and non-small cell lung cancer (NSCLC) survival by utilizing genotyping data from two published genome-wide association studies. We used multivariate Cox proportional hazards regression and expression quantitative trait loci analyses to identify survival-associated SNPs and their correlations with the corresponding mRNA expression, respectively. We also used the Kaplan-Meier survival analysis and bioinformatics functional prediction to further evaluate the identified independent SNPs.

resultsWe found five independent SNPs (

conclusionsGenetic variants of IMPACT: Genetic variants of

Indexed as

AgedApolipoprotein B-100CadherinsCarcinoma, Non-Small-Cell LungCholesterolFemaleGenotypeHaplotypesHumansLung NeoplasmsMaleAPOB protein, humanApolipoprotein B-100CadherinsCholesterolH-cadherin

Identifiers

PMID32238407
PMCPMC7269811
OpenAlexW3014473665

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.